TapImmune, Inc. (TPIV.OB) to Collaborate with Aeras Global to Develop Tuberculosis Vaccine
TapImmune Inc., biotech innovator and developer of therapies for infectious disease and oncology, and creator of the revolutionary TAP vaccine which has ability to restore antigen presentation in cells, announced in February of this year the signing of a letter of intent to begin a collaborative R&D campaign with Aeras Global TB Vaccine Foundation. Aeras is dedicated to moving leading tuberculosis vaccines forward and making worldwide distribution and adoption of them ubiquitous despite age group or income level. Aeras operates under private foundations like The Bill & Melinda Gates Foundation, and accepts governmental aid as a non-profit product development partnership.…